Clinical Trial Update: Antithrombin III in Infants With Cardiopulmonary Bypass (CPB) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating antithrombin III in infants undergoing cardiopulmonary bypass for congenital heart disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease

Drugs mentioned

• Antithrombin III (antithrombin III)

Snippet

Sponsor: University of Rochester | Conditions: Congenital Heart Disease | Phase 1 | Status: TERMINATED